Syntocinon

ApprovedSmall molecule

SShana McCormack, MD

Syntocinon is one of 296 small molecule programs targeting Essential Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

295

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionActive, not recruiting

Frontotemporal DementiaActive, not recruiting

Wound HealingActive, not recruiting

TinnitusActive, not recruiting

CognitionActive, not recruiting

Autism Spectrum DisorderActive, not recruiting

PreeclampsiaActive, not recruiting

Hypothalamic ObesityActive, not recruiting

Cesarean SectionActive, not recruiting

Postpartum HemorrhageActive, not recruiting

Essential HypertensionPreclinical

Active, not recruiting

Frontotemporal DementiaPhase 2

Active, not recruiting

Wound HealingPhase 1

Active, not recruiting

TinnitusPreclinical

Active, not recruiting

CognitionApproved

Active, not recruiting

Autism Spectrum DisorderApproved

Active, not recruiting

PreeclampsiaPreclinical

Active, not recruiting

Hypothalamic ObesityPhase 2

Active, not recruiting

Cesarean SectionPreclinical

Active, not recruiting

Postpartum HemorrhageApproved

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

238 competitors in Essential Hypertension

#DrugCompanyPhaseTrials

Avapro

Sanofi

Phase 3

2 2

Micardis

Boehringer Ingelheim

Phase 3

10 3

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

8 4

Syntocinon

SShana McCormack, MD

Approved

1 5

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

4 6

CS-3150

Daiichi Sankyo

Phase 3

3 7

Fimasartan

Boryung Pharmaceutical Co., Ltd

Phase 3

10 8

Allisartan Isoproxil

SShenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 3

1 9

Coversyl

SServier

Phase 3

1 10

AGSAVI

Ahn-Gook Pharmaceuticals Co.,Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxytocin7 trials

Oxytocin and Approach-avoid in Grief

Completed·UUniversity of Arizona·N/A·NCT04505904·44 enrolled

Oxytocin and Eating

Unknown status·—·Phase 2·NCT03225456·60 enrolled

The Influence of Oxytocin on Pair-bonding and Emotion Regulation

Completed·UUniversity Hospital, Bonn·Phase 1·NCT02501837·40 enrolled

Show 4 more trials

Brain Dynamics of Oxytocin

Completed·SStony Brook University·Phase 1·NCT01834261·51 enrolled

Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo

Completed·UUniversity Hospital, Toulouse·Phase 2·NCT01038570·24 enrolled

The Role of Oxytocin in the Perception of Faces

Completed·RRodrigo Cardenas·Phase 1·NCT02443727·71 enrolled

Influence of Oxytocin on the Startle Reflex and on Its Modulation

Unknown status·UUniversity of Zurich·N/A·NCT01066299·50 enrolled

Cesarean Section2 trials

The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)

Completed·—·Phase 3·NCT02053922·270 enrolled

Ultrasonography for Fluid Assessment in Parturients With Preeclampsia Undergoing Cesarean Section

Completed·MMansoura University··NCT04370847·100 enrolled

Autism Spectrum Disorder2 trials

Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders

Completed·KKU Leuven·Phase 4·NCT02940574·40 enrolled

The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders

Completed·AAlexander Kolevzon·Phase 2·NCT01183221·30 enrolled

Frontotemporal Dementia1 trial

Intranasal Oxytocin for Frontotemporal Dementia

Unknown status·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT03260920·112 enrolled

Obese Adolescents1 trial

Intranasal Oxytocin and Food Intake in Obese Adolescents

Withdrawn·SShana McCormack, MD·Phase 2·NCT03497988

12 more indications

Induction of Labor1 trial

Induction of Labor in Pregnant Women With Prelabor Rupture of Membranes - Oxytocin or Misoprostol

Completed·—·Phase 4·NCT05215873·200 enrolled

Postpartum Hemorrhage1 trial

Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section

Unknown status·—·Phase 4·NCT05110482·38 enrolled

Tinnitus1 trial

Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus

Completed·—·N/A·NCT02508220·15 enrolled

Cognition1 trial

Oxytocin and Emotion Recognition

Completed·UUniversity Hospital Freiburg·Phase 4·NCT01216605·56 enrolled

Essential Hypertension1 trial

The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hypertension

Terminated·IInsel Gruppe AG, University Hospital Bern·N/A·NCT01938911·16 enrolled

Preeclampsia1 trial

Combined Colloids And Crystalloids Versus Crystalloids in Women With Preeclampsia Undergoing Cesarean Delivery

Completed·MMansoura University·N/A·NCT03252496·140 enrolled

Wound Healing1 trial

Oxytocin, Couple Interaction and Wound Healing

Completed·UUniversity of Zurich·Phase 1·NCT01594775·160 enrolled

Post-Traumatic Stress Disorder, PTSD1 trial

The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With Post Traumatic Stress Disorder (PTSD)

Completed·RRambam Health Care Campus·Phase 4·NCT01325168·62 enrolled

Autism1 trial

Intranasal Oxytocin and Learning in Autism

Withdrawn·UUniversity of Minnesota·Phase 2·NCT02090829

Headache1 trial

Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache

Completed·MMedVadis Research Corporation·N/A·NCT00963040·60 enrolled

Hypothalamic Obesity1 trial

Intranasal Oxytocin in Hypothalamic Obesity

Completed·SShana McCormack, MD·Phase 2·NCT02849743·18 enrolled

Trial1 trial

Intramuscular Oxytocics: A Randomised Control Trial

Completed·NNorth Bristol NHS Trust·Phase 3·NCT02216383·5,798 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for Syntocinon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Syntocinon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Syntocinon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shana McCormack, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShana McCormack, MD

Syntocinon

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oxytocin7 trials

Cesarean Section2 trials

Autism Spectrum Disorder2 trials

Frontotemporal Dementia1 trial

Obese Adolescents1 trial

Induction of Labor1 trial

Postpartum Hemorrhage1 trial

Tinnitus1 trial

Cognition1 trial

Essential Hypertension1 trial

Preeclampsia1 trial

Wound Healing1 trial

Post-Traumatic Stress Disorder, PTSD1 trial

Autism1 trial

Headache1 trial

Hypothalamic Obesity1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News